Accessing Iran's Pharmaceutical Market

Iran's pharmaceutical market presents a distinctive challenge for international companies.

It combines a large healthcare system, a substantial domestic pharmaceutical manufacturing base, continued demand for selected imported medicines, active pharmaceutical ingredients, specialized therapies and pharmaceutical technologies, with a regulatory and commercial environment in which market access is shaped by product registration, domestic-production policy, regulated pricing, reimbursement, foreign-exchange availability, sanctions compliance, banking constraints and the structure of the pharmaceutical distribution system.

For a foreign pharmaceutical company, therefore, the first question should not be:

“Can we sell this medicine in Iran?”

A more useful question is:

“Can this particular medicine obtain regulatory access, achieve an economically viable price, be lawfully and practically paid for, imported, distributed and ultimately reach patients in Iran?”

Those are very different questions. A pharmaceutical product may be clinically valuable, internationally approved and commercially successful elsewhere and still lack a viable pathway into the Iranian market. Conversely, a product addressing a significant unmet medical need may justify a structured market-entry process even where regulatory and commercial execution is complex.

That distinction is the starting point for understanding pharmaceutical market access in Iran.

Iran operates a highly regulated pharmaceutical system under the Ministry of Health and Medical Education, with the Iran Food and Drug Administration, or IFDA, playing the central regulatory role in pharmaceutical manufacturing, registration, importation and distribution.[1]Research on the Iranian pharmaceutical system also identifies the national drug-selection process as an important gate through which medicines obtain access to the formal market.[2]

This means that a foreign manufacturer's commercial strategy cannot be separated from its regulatory strategy. In many consumer markets, a company may identify demand, appoint a distributor, ship goods and build sales gradually. Pharmaceuticals work differently.

Product Assessment → Regulatory Eligibility → Local Representation → Registration → Pricing → Reimbursement → Import Authorization → Payment → Customs Clearance → Distribution → Patient Access

Failure at one stage can render every subsequent stage irrelevant. The first serious commercial assessment should therefore take place beforea foreign manufacturer commits substantial resources to registration.

A company should determine whether the medicine is already available in Iran, whether equivalent generic or branded products are domestically manufactured, whether there is an identifiable therapeutic need, how the product fits within Iranian pharmaceutical policy, what competing therapies exist, what regulatory pathway is likely to apply and whether the probable regulated price can support the economics of importation.

This is particularly important because Iran has pursued a sustained policy of supporting domestic pharmaceutical production. A WHO-published study using 2021 pharmaceutical-consumption data reported that domestic manufacturers supplied approximately 98.5% of Iran's pharmaceutical market by volume and 87% by value. The same study reported very low availability of originator brands compared with generic products and noted the policy preference for domestic production where reliable domestic generic alternatives exist.[3]

That fact fundamentally changes the market-entry calculation. Iran should not be approached as a conventional import market in which every internationally successful brand can simply appoint a distributor and compete freely against local products.

A foreign company's strongest product globally may not be its strongest candidate for Iran. A highly specialized therapy with limited domestic alternatives may present a more realistic opportunity than a conventional branded medicine competing against several established local generics.

That makes portfolio screening the logical first stage of market entry. Before initiating registration, the manufacturer should review each product individually: active ingredient, dosage form, strength, indication, manufacturing site, GMP position, international approvals, local alternatives, expected patient population, annual demand, storage requirements, shelf life, likely pricing and the possibility of domestic substitution.

Only after this analysis should the company decide which products justify regulatory investment.

The next major issue is local representation. Foreign pharmaceutical manufacturers generally do not operate in Iran simply as detached overseas sellers. Registration, regulatory communication, importation and post-market obligations usually require a structured relationship with an Iranian entity capable of acting within the local regulatory system.

Published analyses of IFDA procedures describe imported medicines as being submitted through an official local representative, with regulatory review covering the approved source, quality documentation and product-specific requirements.[4]

That makes partner selection one of the most important commercial decisions in the entire process. A local partner may potentially assist with regulatory submissions, communications with IFDA, pricing procedures, import documentation, customs clearance, pharmacovigilance, warehousing, distribution, hospital access and commercial development.

But these functions should not automatically be entrusted to the same company without analysis. A company may be strong in regulatory affairs but weak in distribution. Another may possess hospital relationships but limited experience with imported products. A third may have significant sales capacity but inadequate compliance controls.

The manufacturer should therefore conduct due diligence before granting exclusivity. That assessment should examine corporate ownership, licences, regulatory experience, therapeutic-area expertise, financial capacity, warehousing capability, compliance systems, distribution network, pharmacovigilance capability, litigation or regulatory history and actual experience registering foreign pharmaceutical products.

Exclusivity deserves particular caution. Granting a broad, long-term exclusive right before the product has been registered can create substantial problems if the representative fails to progress the dossier, cannot secure a commercially viable price or proves ineffective after launch.

Dossier Submission → Regulatory Progress → Pricing Approval → First Import → Minimum Sales → Continued Compliance

The contract should also address ownership and control of regulatory documentation, trademarks, confidential information, pharmacovigilance responsibilities, recalls, product complaints, termination rights and the treatment of pending registrations if the relationship ends.

In pharmaceuticals, the local representative is not merely a buyer. It can become part of the product's regulatory infrastructure.

Registration is the next major gate. Iran maintains its own pharmaceutical registration process, and international approval alone should not be treated as equivalent to Iranian market authorization. Published studies of IFDA procedures describe dossier review, GMP-related requirements, quality evaluation and other regulatory controls within the registration process.[4]

For companies familiar with CTD-style submissions, much of the scientific architecture will be recognizable. The dossier may involve information concerning the manufacturer and manufacturing site, formulation, active ingredients and excipients, manufacturing processes, specifications, analytical methods, stability, packaging, labeling, clinical and non-clinical evidence where applicable, quality certificates and evidence of approvals in other jurisdictions.

But a technically complete international dossier does not guarantee rapid Iranian market access. A 2024 study comparing IFDA approval of new molecular entities with the U.S. FDA, EMA and Japan's PMDA found substantial approval lags. Among medicines approved by both IFDA and FDA, the study reported a mean relative lag of approximately 65 months; comparisons with EMA and PMDA also showed significant delays.[5]

Do not build the business plan around an assumed registration date.

Registration is only one layer of market access.Pricing may determine whether registration has commercial value at all.

Iran's pharmaceutical market is heavily price regulated. Research on the Iranian pricing system describes a Pharmaceutical Pricing Commission within the IFDA framework and identifies regulated pricing methods for both imported and locally manufactured medicines.[6]

Imported pharmaceuticals have historically been subject to reference-pricing mechanisms, while newer medicines may also be assessed using value-based approaches and other complementary methods. A 2023 analysis of Iran's external reference-pricing system found that ERP remains an important tool but is not used in isolation; the study describes value-based pricing as the principal method for new molecules, with reference pricing applied as a complementary mechanism.[7]

For a foreign manufacturer, the critical point is not the technical name of the pricing methodology. It is that the company cannot simply take its international transfer price, add importer and distributor margins and assume that the resulting number will become the Iranian market price.

Target Price → Regulatory Price → Import Cost → Distribution Margin → Currency Exposure → Net Manufacturer Revenue

Sensitivity analysis is essential. If the transaction is viable only at one assumed exchange rate or one expected regulatory price, the business model may be too fragile.

Reimbursement creates another layer. A registered and priced medicine is not necessarily equally accessible to all patients. Insurance coverage, indication, reimbursement rules and patient co-payments can materially affect real demand.

WHO research on Iran describes a pharmaceutical system in which insurance plays an important role in medicine reimbursement and pharmacies obtain medicines through officially registered pharmaceutical distributors, subject to limited exceptions for certain products.[8]

Eligible Patients × Diagnosed Patients × Accessible Patients × Reimbursed Patients × Achievable Price

A theoretical patient population may be far larger than the economically accessible market.

Once regulatory and pricing viability have been established, attention turns to importation. Pharmaceutical imports should not be treated as ordinary customs shipments. The consignment must correspond to the approved product, manufacturing source, specifications and documentation. Shipment-level regulatory documentation can become relevant to release, banking and distribution.[4]

Approved Manufacturer → Approved Product → Authorized Import Structure → Regulatory Documentation → Customs → Authorized Pharmaceutical Distribution

Batch documents, certificates of analysis, storage conditions, manufacturing records, shipment documentation and remaining shelf life can all become operationally important.

For temperature-sensitive medicines, vaccines, biologics and other specialty products, cold-chain integrity becomes part of regulatory compliance. A shipment that physically reaches Iran but cannot demonstrate acceptable storage conditions is not a successful import.

Distribution presents another key issue. Medicines in Iran generally move through regulated pharmaceutical distribution channels rather than conventional consumer-goods wholesalers. WHO research describes pharmacies as obtaining medicines from officially registered pharmaceutical distributors, apart from limited specialized exceptions.[8]

For a foreign manufacturer, therefore, appointing an importer does not automatically solve distribution. The company must understand what happens after customs clearance.

Who warehouses the product? Which distributor carries it? Which hospitals or pharmacies can order it? Who monitors expiry dates? Who manages returns? Who provides sales data? Who handles pharmacovigilance reporting? And most importantly: who develops the market?

They may coexist within one partner. Often they do not.

Inventory planning also requires care. Pharmaceutical supply chains everywhere have to balance product availability against expiry risk, but the challenge becomes greater when registration, foreign exchange, banking and import timing are uncertain.

Demand × Lead Time × Regulatory Delay × Payment Delay × Safety Stock × Shelf Life

A foreign manufacturer accustomed to predictable European replenishment cycles may need a very different inventory model for Iran.

The sanctions issue deserves particular precision. It is inaccurate to reduce the position to:

“Medicines are exempt from sanctions.”

U.S. sanctions rules contain broad humanitarian exceptions and authorizations that allow many transactions involving medicines and medical devices, subject to defined conditions. OFAC states that the commercial sale and export of humanitarian goods, including medicines and medical devices, to Iran may be permitted under existing exemptions, exceptions and general licences.[9]

OFAC also confirms that non-U.S. persons may export or re-export qualifying medicines and medical devices subject to the EAR under the relevant general licences where all applicable conditions are satisfied.[10]

But the humanitarian framework is not unlimited. OFAC's TSRA guidance expressly notes that while many medicines and medical devices are EAR99, certain vaccines, biological and chemical products, devices and components appear on the Commerce Control List and may not qualify under the same general authorization.[11]

Counterparties also matter. For non-U.S. persons, OFAC FAQ 844 states that ordinary humanitarian transactions involving medicine generally do not trigger U.S. secondary sanctions merely because the transaction involves Iran, while preserving restrictions relating to certain designated persons and institutions.[12]

Humanitarian character does not eliminate transaction-specific compliance.

Product → Classification → Origin → Technology → Counterparty → Ownership → Bank → Payment → Carrier → End User → End Use

A second distinction is equally important:legal permissibility is not the same as practical bankability.

A transaction may be lawful and still fail because no bank is willing to process it. A carrier may refuse the shipment. An insurer may decline coverage. A correspondent bank may reject payment. A manufacturer's own compliance department may impose a stricter internal policy than the law itself requires.

This is why a pharmaceutical company should verify the payment structurebefore manufacturing or shipping against an Iranian order.

OFAC's continuing administration of the TSRA licensing regime demonstrates that this framework remains operational in 2026. On 30 June 2026, OFAC published a quarterly report covering January–March 2026 and confirmed that it continues processing licence applications for exports of agricultural commodities, medicines and medical devices to Iran under TSRA.[13]

Foreign-exchange risk creates a separate problem. Even where a transaction is legally permissible and regulatory approval exists, the Iranian importer may face constraints concerning access to foreign currency, timing of payment and the exchange-rate basis of the transaction.

These questions belong in the contract. A purchase order is not equivalent to collectible revenue.

Quality obligations continue after importation. The manufacturer's responsibilities do not end when the goods clear customs. Post-marketing surveillance, adverse-event reporting, complaints, recalls and safety communications remain fundamental parts of pharmaceutical market access.

The local agreement should clearly allocate responsibility for adverse-event collection, expedited safety reporting, product-quality complaints, batch traceability, recalls, regulatory communications and record retention.

The strength of Iran's domestic pharmaceutical industry also means that finished-product importation should not automatically be treated as the best long-term model. WHO's 2024 data confirm the dominance of domestic manufacturing by volume and value.[3]

No structure is universally superior. Finished-product importation preserves greater manufacturing control but may face stronger pricing and policy constraints. Local production may improve long-term market positioning but requires deeper commitment, partner due diligence, intellectual-property protection and quality oversight. Licensing reduces certain capital requirements but may reduce commercial control. API supply may fit established Iranian manufacturing capability while placing the foreign company further upstream from the patient.

This leads to a broader point:Iran is not one pharmaceutical market.

The commercial environment for a conventional generic tablet is completely different from that of an oncology biologic. A vaccine is different from a hospital injectable. An orphan drug is different from an OTC medicine. An API supplier faces different regulatory and commercial questions from a finished-dose manufacturer. A company supplying production technology is entering another market entirely.

Product + Therapeutic Area + Regulatory Pathway + Supply Model + Price + Payment + Distribution Channel

Headline estimates of total pharmaceutical-market size can therefore be misleading. They may provide macroeconomic context, but they often say little about the opportunity available to a particular international manufacturer.

The WHO study published in 2024 found that originator-brand availability was below 10% across the sectors studied, while generic availability was significantly higher. It also found that only 20% of the surveyed originator brands met the study's affordability criterion, compared with approximately 95% or more for the generic categories examined.[3]

For an international pharmaceutical company, this is a warning against confusing total pharmaceutical demand with accessible imported-product demand.

A disciplined manufacturer can therefore approach Iran through a series of gates: is there genuine clinical and commercially accessible demand? Is there a realistic regulatory pathway? Can an economically viable price be achieved? Is the transaction permissible under all applicable sanctions and export-control regimes? Can a compliant and workable payment channel be established? Can the product be imported, stored and distributed through an appropriate pharmaceutical supply chain?

Market Demand → Regulatory Access → Pricing → Compliance → Payment → Import → Distribution → Patient

The chain is only as strong as its weakest link.

The first commercial shipment should therefore be treated as a controlled implementation exercise rather than the completion of the market-entry project. Measure what actually happens: regulatory timing, import timing, payment execution, document acceptance, temperature control, inventory movement, reimbursement barriers, pharmacovigilance performance and actual net manufacturer revenue.

Those answers should determine the scale of the second shipment. Not the assumptions in the original business plan.

A foreign manufacturer considering Iran is evaluating the Iranian partner at the same time that the Iranian company is evaluating the product. The strongest partner is therefore not necessarily the one promising the highest sales volume.

Regulatory Capability → Pricing Knowledge → Compliance → Finance → Importation → Distribution → Market Development → Pharmacovigilance

In a complex market, execution capability is itself a commercial asset.

Iran's pharmaceutical market should therefore be approached neither as an inaccessible market nor as a simple humanitarian-trade exception. Both descriptions are incomplete.

Iran has a substantial domestic pharmaceutical industry and policies that strongly support local production. Domestic products account for the overwhelming majority of medicine consumption by volume.[3]At the same time, imported specialized medicines, APIs, technologies and international pharmaceutical partnerships can have a meaningful role where therapeutic need, regulatory policy and commercial conditions align.

Sanctions complicate execution but do not eliminate pharmaceutical trade. U.S. rules maintain significant humanitarian exceptions and authorizations for qualifying medicines and medical devices, while requiring transaction-specific attention to product classification, counterparties and applicable restrictions.[9][10][11][12]

The practical challenge is therefore not merely obtaining permission to sell a medicine. It is aligning several systems simultaneously:

When those systems align, market entry becomes executable. When even one does not, a medicine can be internationally approved, clinically valuable, registered and commercially desired—and still fail to reach the Iranian patient.

That is the central reality of pharmaceutical market access in Iran:the objective is not merely to register a medicine. It is to build a complete, compliant and commercially sustainable pathway from the global manufacturer to the patient.